Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

112.56 -0.05 (-0.04%)
Streaming Delayed Price Updated: 10:41 AM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 703,877
Open 112.31
Bid (Size) 112.54 (5)
Ask (Size) 112.58 (1)
Prev. Close 112.61
Today's Range 112.10 - 112.93
52wk Range 89.67 - 121.64
Shares Outstanding 1,750,942,289
Dividend Yield 1.81%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
These dividend players could lift your portfolio no matter what the market is doing. 
Via The Motley Fool
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation. 
Via Benzinga

Performance

YTD
+2.47%
+2.47%
1 Month
-0.12%
-0.12%
3 Month
+7.32%
+7.32%
6 Month
-0.81%
-0.81%
1 Year
+16.97%
+16.97%

More News

Read More
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why ABBOTT LABORATORIES (NYSE:ABT) should be investigated by quality investors.
Via Chartmill
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
Abbott Laboratories Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
Via The Motley Fool
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
Via The Motley Fool
3 Stocks to Buy and Hold Forever
Via The Motley Fool
3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold
Via The Motley Fool
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
Via The Motley Fool
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
Via MarketBeat
Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Abbott's 'Transformative' Move And Answer To Dexcom's Newest Device
Via Investor's Business Daily
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
Via The Motley Fool
Patchy But Still Bullish
Via Talk Markets
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Via Benzinga
Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
Via Benzinga
Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?
Via Investor's Business Daily
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
Via The Motley Fool
Donald Trump Owns These 21 Dividend Kings. Should You?
Via The Motley Fool
Topics Government
Exposures Political
3 Unstoppable Dividend Stocks to Buy Right Now
Via The Motley Fool
Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally
Via MarketBeat
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.